Literature DB >> 8472351

Carnitine measurements in liver, muscle tissue, and blood in normal subjects.

P Harper1, C Wadström, G Cederblad.   

Abstract

We determined carnitine concentrations in blood and in liver and abdominal muscle biopsy specimens in 13 men and 16 women undergoing elective surgery (mostly gallbladder removal). The data suggest that the carnitine pools of plasma and erythrocytes are different. The erythrocytes show a higher acylcarnitine concentration than does plasma (P < 0.001). Several reference bases for values in tissues have been used--dry weight, noncollagen protein (NCP), and DNA--because these may be differently influenced by disease. In liver specimens, the quotient NCP (g)/DNA (g) was significantly higher in men, 54.4 +/- 6.3 (mean +/- SD), than in women, 47.7 +/- 7.0 (P < 0.01). Liver total carnitine content in relation to DNA was significantly higher in men than in women: 0.29 +/- 0.06 vs 0.22 +/- 0.08 mmol/g DNA (P < 0.01). Free carnitine content was significantly higher in men than in women independently of the reference base, e.g., 3.7 +/- 1.0 mumol/g NCP for men vs 2.9 +/- 1.0 for women (P < 0.05). No difference was found between the sexes in the abdominal muscle carnitine content, 20.6 +/- 6.7 mumol/g NCP for men vs 17.9 +/- 5.0 for women. Our study establishes control ranges, thereby providing an important basis for studies of patients with abnormal carnitine metabolism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8472351

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  9 in total

Review 1.  Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects.

Authors:  Stephanie E Reuter; Allan M Evans
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

2.  Clinical and environmental influences on metabolic biomarkers collected for newborn screening.

Authors:  Kelli K Ryckman; Stanton L Berberich; Oleg A Shchelochkov; Daniel E Cook; Jeffrey C Murray
Journal:  Clin Biochem       Date:  2012-09-23       Impact factor: 3.281

3.  Carnitine and physical exercise.

Authors:  O J Heinonen
Journal:  Sports Med       Date:  1996-08       Impact factor: 11.136

4.  The variation of carnitine content in human blood cells during disease--a study in bacterial infection and inflammatory bowel disease.

Authors:  M Demirkol; A C Sewell; H Böhles
Journal:  Eur J Pediatr       Date:  1994-08       Impact factor: 3.183

Review 5.  Pharmacokinetics of L-carnitine.

Authors:  Allan M Evans; Gianfranco Fornasini
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  A mitochondria-targeted fatty acid analogue influences hepatic glucose metabolism and reduces the plasma insulin/glucose ratio in male Wistar rats.

Authors:  Carine Lindquist; Bodil Bjørndal; Hege G Bakke; Grete Slettom; Marie Karoliussen; Arild C Rustan; G Hege Thoresen; Jon Skorve; Ottar K Nygård; Rolf Kristian Berge
Journal:  PLoS One       Date:  2019-09-24       Impact factor: 3.240

7.  Multi-omics insights into functional alterations of the liver in insulin-deficient diabetes mellitus.

Authors:  Mattias Backman; Florian Flenkenthaler; Andreas Blutke; Maik Dahlhoff; Erik Ländström; Simone Renner; Julia Philippou-Massier; Stefan Krebs; Birgit Rathkolb; Cornelia Prehn; Michal Grzybek; Ünal Coskun; Michael Rothe; Jerzy Adamski; Martin Hrabĕ de Angelis; Rüdiger Wanke; Thomas Fröhlich; Georg J Arnold; Helmut Blum; Eckhard Wolf
Journal:  Mol Metab       Date:  2019-06-04       Impact factor: 7.422

Review 8.  Newborn Screening Samples for Diabetes Research: An Underused Resource.

Authors:  Jane Frances Grace Lustre Estrella; Jincy Immanuel; Veronica Wiley; David Simmons
Journal:  Cells       Date:  2020-10-15       Impact factor: 6.600

9.  Association of amino acids with common complications of prematurity.

Authors:  Kelli K Ryckman; John M Dagle; Oleg A Shchelochkov; Noah Ehinger; Stanley D Poole; Stanton L Berberich; Jeff Reese; Jeffrey C Murray
Journal:  Pediatr Res       Date:  2013-03-12       Impact factor: 3.756

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.